DS
KRYS icon

David Shaw’s Krystal Biotech KRYS Stock Holding History

David Shaw’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-996
Closed -$298K – 5060
2026
Q1 		$257K Sell
996
-1,112
-53% -$296K ﹤0.01% 4119
2025
Q4 		$520K Sell
2,108
-4,706
-69% -$990K ﹤0.01% 3913
2025
Q3 		$1.2M Sell
6,814
-4,913
-42% -$735K ﹤0.01% 3346
2025
Q2 		$1.61M Sell
11,727
-38,165
-76% -$5.61M ﹤0.01% 2903
2025
Q1 		$9M Buy
49,892
+42,465
+572% +$7.14M 0.01% 1477
2024
Q4 		$1.16M Sell
7,427
-1,919
-21% -$340K ﹤0.01% 3117
2024
Q3 		$1.7M Sell
9,346
-1,700
-15% -$328K ﹤0.01% 2833
2024
Q2 		$2.03M Sell
11,046
-70,981
-87% -$11.9M ﹤0.01% 2646
2024
Q1 		$14.6M Buy
82,027
+14,886
+22% +$2.07M 0.01% 1119
2023
Q4 		$8.33M Buy
67,141
+11,384
+20% +$1.26M 0.01% 1500
2023
Q3 		$6.47M Buy
55,757
+45,962
+469% +$5.61M 0.01% 1600
2023
Q2 		$1.15M Buy
9,795
+4,200
+75% +$429K ﹤0.01% 2996
2023
Q1 		$448K Sell
5,595
-805
-13% -$63.2K ﹤0.01% 3601
2022
Q4 		$507K Sell
6,400
-1,700
-21% -$126K ﹤0.01% 3841
2022
Q3 		$565K Hold
8,100
– – ﹤0.01% 3969
2022
Q2 		$532K Buy
8,100
+4,291
+113% +$267K ﹤0.01% 4053
2022
Q1 		$253K Buy
+3,809
New +$238K ﹤0.01% 4740
2021
Q4 		– Sell
-13,571
Closed -$709K – 5557
2021
Q3 		$709K Buy
13,571
+6,331
+87% +$375K ﹤0.01% 3859
2021
Q2 		$492K Buy
+7,240
New +$505K ﹤0.01% 4042

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

David Shaw's KRYS Position: Q2 2026 in Review

David Shaw sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 996 shares — an estimated $298K sold.

David Shaw first reported a position in KRYS in Q2 2021 and held it in 19 quarters. The position peaked at $14.6M in Q1 2024. 420 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • David Shaw reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • David Shaw sold 996 Krystal Biotech shares in Q2 2026, an estimated $298K.
  • David Shaw first reported a position in Krystal Biotech in Q2 2021 and held it in 19 quarters.
  • David Shaw's Krystal Biotech position peaked at $14.6M in Q1 2024.
  • 420 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.